Post-earnings recap
Reported
Wed, Feb 15, 2023
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
88%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
The earnings report shows that 10X Genomics exceeded expectations on EPS, which likely contributed to the stock's 3.3% increase. The company did not provide revenue figures or future guidance, leaving some uncertainty. However, management's positive comments about demand and innovation suggest a focus on growth moving forward.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.15 | N/A | +48.28% |
| Revenue | N/A | N/A | N/A |
Overall, management expressed a positive outlook on product demand and innovation. They acknowledged market challenges but remain focused on growth.
Management highlighted the continued demand for their products despite market challenges.
They emphasized their focus on innovation and expanding their customer base.